Photo: Paolo Tarantino/Twitter
Jun 10, 2023, 02:53
Patients progressing on 1L palbo should not receive further exposure to palbo- Paolo Tarantino
Consistent with the PACE trial, the PALMIRA randomized phase 2 trial showed no benefit in terms of PFS or OS with the use of palbociclib beyond progression to 1L ET+palbo. Patients progressing on 1L palbo should not receive further exposure to palbo. #ASCO23
Source: Paolo Tarantino/Twitter